SML3457

JX06

≥98% (HPLC)

• Synonim(y): 4,4′-(Dithiodicarbonothioyl)bis[morpholine], 4-Morpholinethiocarbonyl disulfide, Bis(4-morpholinethiocarbonyl) disulfide, Bis(oxydi-2,1-ethanediyl)-thiuram disulfide, Dimorpholinethiuram disulfide, JX 06, JX-06, NSC 402538
• Wzór empiryczny (zapis Hilla): C₁₀H₁₆N₂O₂S₄
• Numer CAS: 729-46-4
• Masa cząsteczkowa: 324.51
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD00072237
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C
• SMILES string: S(SC(=S)N2CCOCC2)C(=S)N1CCOCC1
• InChI: 1S/C10H16N2O2S4/c15-9(11-1-5-13-6-2-11)17-18-10(16)12-3-7-14-8-4-12/h1-8H2
• InChI key: KKVYOWPPMNSLCP-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

JX06 is a potent, PDK1-selective, covalent pyruvate dehydrogenase (PDH) kinase (PDHK, PDK) inhibitor (PDK1/2/3 IC50 = 49/101/313 nM; PDK4 IC50 >10 µM, IC50 >10 µM against >300 other kinases). JX06 inhibits cellular PDK substrate PDHA1 Ser293/232 phosphorylation, resulting in reduced aerobic glycolysis and cancer proliferation in cultures (1-10 µM) and in mice in vivo (40-80 mg/kg via daily i.p. injection; A549 & HT-29 xenografts). JX06 is shown to target PDK1 Cys240 for covalent modification.

Potent, PDK1-selective, covalent pyruvate dehydrogenase kinase (PDHK, PDK) inhibitor with anti-cancer efficacy in vitro and in vivo.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS07
• signalword: Warning
• hcodes: H315,H319
• pcodes: P264 - P280 - P302 + P352 - P305 + P351 + P338 - P332 + P313 - P337 + P313
• Hazard Classifications: Eye Irrit. 2 - Skin Irrit. 2
• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable